Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Cardiotoxicity 14Breast Neoplasms 11Lymphoma, Non-Hodgkin 5Neoplasms 4Lymphoma 4Heart Failure 4Prostatic Neoplasms 2Multiple Myeloma 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia 2Heart Diseases 2Cardiovascular Diseases 2Burkitt Lymphoma 2Ventricular Dysfunction, Left 1Ventricular Dysfunction 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Obesity 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1Mesothelioma 1Memory Disorders 1

Interventions

Etoposide 9Rituximab 8Cyclophosphamide 7Vincristine 6Prednisone 6Doxorubicin 5Filgrastim 4Cytarabine 3Radiotherapy 2Procarbazine 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lomustine 2Carmustine 2prednylidene 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1ibrutinib 1ibritumomab tiuxetan 1etoposide phosphate 1efavirenz 1deltacortene 1VAP-cyclo protocol 1Ultrasonography 1Radioimmunotherapy 1Ondansetron 1O(6)-benzylguanine 1Mitoguazone 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, AIDS-Related × Echocardiography × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡